Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

miltefosine

  • Leishmanicidal Activity of an <em>In Silico</em>-Screened Novel Inhibitor against Ascorbate Peroxidase of <span class="named-content genus-species" id="named-content-1">Leishmania donovani</span>
    Mechanisms of Action: Physiological Effects
    Leishmanicidal Activity of an In Silico-Screened Novel Inhibitor against Ascorbate Peroxidase of Leishmania donovani

    Peroxidases are a heterogeneous family of enzymes that have diverse biological functions. Ascorbate peroxidase is a redox enzyme that is reduced by trypanothione, which plays a central role in the redox defense system of Leishmania. In view of developing new and novel therapeutics, we performed in silico studies in order to search for a ligand library and identify new drug candidates and their physiological roles...

    Mohammad Kashif, Ankush Paladhi, Ranjeet Singh, Sankar Bhattacharyya, Sumit Kumar Hira, Partha Pratim Manna
  • <em>In Vitro</em> Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen <span class="named-content genus-species" id="named-content-1">Candida auris</span> to Miltefosine Alone and in Combination with Amphotericin B
    Letter to the Editor
    In Vitro Antifungal Susceptibility of the Emerging Multidrug-Resistant Pathogen Candida auris to Miltefosine Alone and in Combination with Amphotericin B
    Yongqin Wu, Marissa Totten, Warda Memon, Chunmei Ying, Sean X. Zhang
  • Minimal Cerebrospinal Fluid Concentration of Miltefosine despite Therapeutic Plasma Levels during the Treatment of Amebic Encephalitis
    Clinical Therapeutics
    Minimal Cerebrospinal Fluid Concentration of Miltefosine despite Therapeutic Plasma Levels during the Treatment of Amebic Encephalitis

    Miltefosine is an alkylphosphocholine compound that is used primarily for treatment of leishmaniasis and demonstrates in vitro and in vivo antiamebic activity against Acanthamoeba species. Recommendations for treatment of amebic encephalitis generally include miltefosine therapy. Data indicate that treatment with an amebicidal concentration of at least 16 μg/ml of miltefosine is required for most ...

    Marguerite L. Monogue, Durward Watson, Julie S. Alexander, Dominick Cavuoti, Laura M. Doyle, Michael Zhuo Wang, Bonnie C. Prokesch
  • Open Access
    Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite <span class="named-content genus-species" id="named-content-1">Trypanosoma brucei</span>
    Mechanisms of Resistance
    Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei

    The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by toxicity and emergent resistance. Furthermore, our understanding of drug mode of action and potential routes to resistance is limited. Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite ...

    Clare F. Collett, Carl Kitson, Nicola Baker, Heather B. Steele-Stallard, Marie-Victoire Santrot, Sebastian Hutchinson, David Horn, Sam Alsford
  • Open Access
    Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation
    Pharmacology
    Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation

    Host immune responses are pivotal for the successful treatment of the leishmaniases, a spectrum of infections caused by Leishmania parasites. Previous studies speculated that augmenting cytokines associated with a type 1 T-helper cell (Th1) response is necessary to combat severe forms of leishmaniasis, and it has been hypothesized that the antileishmanial drug miltefosine is capable of immunomodulation and induction of Th1...

    Semra Palić, Patrick Bhairosing, Jos H. Beijnen, Thomas P. C. Dorlo
  • Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice
    Experimental Therapeutics
    Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice

    We evaluated the efficacy of azithromycin (50 mg/kg, every 12 h [q12h] orally) and miltefosine (25 mg/kg, q24h orally) treatments in an experimental model of vascular/disseminated pythiosis in immunosuppressed mice. Azithromycin was the only treatment able to reduce mortality.

    Erico S. Loreto, Juliana S. M. Tondolo, Francielli P. K. de Jesus, Camila M. Verdi, Carla Weiblen, Maria I. de Azevedo, Glaucia D. Kommers, Janio M. Santurio, Régis A. Zanette, Sydney H. Alves
  • Miltefosine Reduces the Cytolytic Activity and Virulence of <em>Acinetobacter baumannii</em>
    Experimental Therapeutics
    Miltefosine Reduces the Cytolytic Activity and Virulence of Acinetobacter baumannii

    Stagnation in antimicrobial development has led to a serious threat to public health because some Acinetobacter baumannii infections have become untreatable. New therapeutics with alternative mechanisms of action to combat A. baumannii are therefore necessary to treat these infections.

    ...
    Steven E. Fiester, Brock A. Arivett, Amber C. Beckett, Benjamin R. Wagner, Emily J. Ohneck, Robert E. Schmidt, Jennifer T. Grier, Luis A. Actis
  • Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in <span class="named-content genus-species" id="named-content-1">Leishmania donovani</span> by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages
    Mechanisms of Resistance
    Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages

    The oral drug miltefosine (MIL) was introduced in the Indian subcontinent in the year 2002 for the treatment of visceral leishmaniasis (VL). However, recent reports on its declining efficacy and increasing relapse rates pose a serious concern.

    Deepak Kumar Deep, Ruchi Singh, Arpita Kulshrestha, Saima Wajid, Poonam Salotra
  • Mechanisms of Action: Physiological Effects
    Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts

    Cryptococcus spp. are common opportunistic fungal pathogens, particularly in HIV patients.

    Cristina de Castro Spadari, Taissa Vila, Sonia Rozental, Kelly Ishida
  • Open Access
    Mechanisms of Action: Physiological Effects
    Complex Interplay between Sphingolipid and Sterol Metabolism Revealed by Perturbations to the Leishmania Metabolome Caused by Miltefosine
    Emily G. Armitage, Amjed Q. I. Alqaisi, Joanna Godzien, Imanol Peña, Alison J. Mbekeani, Vanesa Alonso-Herranz, Ángeles López-Gonzálvez, Julio Martín, Raquel Gabarro, Paul W. Denny, Michael P. Barrett, Coral Barbas

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596